ACADIA Pharmaceuticals Inc. (ACAD) Stock

NASDAQ: ACADBiopharmaceutical company specializing in the development and commercialization of treatments for central nervous system disorders.

ACADIA Pharmaceuticals stock price chart

ACAD interactive chart →

ACAD stock quote & key statistics

ACADIA Pharmaceuticals earnings per share

Income →
Earnings per share

ACADIA Pharmaceuticals revenue & net income

Income →
RevenueNet income

ACADIA Pharmaceuticals annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$1.07B$391.0M$0.67
FY2024$957.8M$226.5M$1.36
FY2023$726.4M-$61.3M-$0.38
FY2022$517.2M-$216.0M-$1.34
FY2021$484.1M-$167.9M-$1.05

Fiscal year ending December 31. Source: company filings via EODHD.

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a prominent biopharmaceutical enterprise headquartered in San Diego, California, is dedicated to advancing innovative therapies that address critical unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company's flagship product, NUPLAZID (pimavanserin), is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis, offering a crucial therapeutic option in this challenging condition. ACADIA's robust pipeline includes Trofinetide, a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1, currently under development for the treatment of Rett Syndrome.

ACADIA Pharmaceuticals is also actively progressing Pimavanserin through the Phase III ADVANCE-2 study, evaluating its efficacy in addressing the negative symptoms of schizophrenia. Additionally, the company is advancing ACP-204 for the treatment of Alzheimer's disease psychosis, along with antisense oligonucleotide programs and other initiatives targeting neuropsychiatric symptoms.

The company's strategic colaborations strengthen its innovation capabilities significantly. ACADIA has entered into a license agreement with Neuren Pharmaceuticals Limited for the development and commercialization of Trofinetide across multiple indications, including Rett syndrome. Furthermore, a collaboration with Stoke Therapeutics, Inc. aims to discover, develop, and commercialize RNA-based medicines for severe and rare genetic neurodevelopmental diseases of the CNS.

Founded in 1993 as Receptor Technologies, Inc. and subsequently rebranded in 1997, ACADIA Pharmaceuticals continues to drive forward with a mission to transform the treatment landscape for CNS disorders and rare diseases. Through a steadfast commitment to scientific rigor and patient-centric innovation, ACADIA remains at the forefront of pioneering therapies that offer hope and improve outcomes for individuals facing challenging neurological conditions.

ACADIA Pharmaceuticals stock FAQ

What is the ACADIA Pharmaceuticals stock ticker symbol?

ACADIA Pharmaceuticals Inc. trades on the NASDAQ under the ticker symbol ACAD.

What sector and industry is ACADIA Pharmaceuticals in?

ACADIA Pharmaceuticals Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals Inc. has about 796 full-time employees.

What were ACADIA Pharmaceuticals's revenue and earnings last fiscal year?

ACADIA Pharmaceuticals reported revenue of $1.07B and net income of $391.0M in fiscal 2025, with earnings per share of $0.67. Revenue grew 11.9% from the prior year.

Is ACADIA Pharmaceuticals in the S&P SmallCap 600?

Yes. ACADIA Pharmaceuticals Inc. (ACAD) is a component of the S&P SmallCap 600, the benchmark index of profitable U.S. small-cap stocks.

Is ACADIA Pharmaceuticals in the Russell 2000?

Yes. ACADIA Pharmaceuticals Inc. (ACAD) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did ACADIA Pharmaceuticals go public?

ACADIA Pharmaceuticals stock began trading on May 27, 2004.

S&P SmallCap 600 Biotechnology stocks

All S&P SmallCap 600 →